Literature DB >> 2846630

The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.

M L Swahn1, E Johannisson, V Daniore, B de la Torre, M Bygdeman.   

Abstract

Seventeen healthy women aged 24-45 years with regular menstrual periods, proven fertility and not using steroidal contraceptives or IUD were recruited for the study. The volunteers were followed during one control, one treatment and one follow-up cycle. Daily morning urine samples were obtained during the control and the treatment cycle. The samples were analysed with regard to pregnanediol glucuronide (P2-G), oestrone glucuronide (E1-G), oestradiol (E2), progesterone (P4), LH and creatinine. During the entire 3-month study the subjects kept a record of uterine bleeding and side effects. The subjects received 50 mg RU486 daily either on cycle days 7-10 (n = 7) or on cycle days 20-23 (n = 10). An endometrial biopsy was taken on cycle day 10 in the first group and on cycle days 21-28 in the second group of patients. Treatment during the proliferative phase caused significant prolongation of the cycle length due to a delay of the oestrogen and LH surge. However, once the oestrogen concentration started to increase, the remaining part of the cycle was normal. The length of the follow-up cycle was similar to that of the control cycle. The morphology of the endometrium did not differ from control samples taken from untreated women at the same time of the cycle. All ovulating women (n = 9) treated in the mid-luteal phase started to bleed on the 3rd to 4th day of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Keywords:  Biology; Drugs--administraction and dosage; Drugs--pharmacodynamics; Endocrine System--changes; Endometrium--changes; Estradiol--analysis; Estrogens; Examinations And Diagnoses; Genitalia; Genitalia, Female; Gonadotropins; Gonadotropins, Pituitary; Hormone Receptors; Hormones; Laboratory Examinations And Diagnoses; Luteinizing Hormone--analysis; Membrane Proteins; Menstrual Cycle; Menstruation; Physiology; Progestational Hormones; Progesterone--analysis; Reproduction; Treatment; Urogenital System; Uterus

Mesh:

Substances:

Year:  1988        PMID: 2846630     DOI: 10.1093/oxfordjournals.humrep.a136809

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

Review 1.  Genetic predisposition for multiple myeloma.

Authors:  Maroulio Pertesi; Molly Went; Markus Hansson; Kari Hemminki; Richard S Houlston; Björn Nilsson
Journal:  Leukemia       Date:  2020-01-08       Impact factor: 11.528

2.  Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914.

Authors:  Pamela Stratton; Eric D Levens; Beth Hartog; Johann Piquion; Qingxiang Wei; Maria Merino; Lynnette K Nieman
Journal:  Fertil Steril       Date:  2009-02-06       Impact factor: 7.329

Review 3.  Medical methods for mid-trimester termination of pregnancy.

Authors:  Hajo Wildschut; Marieke I Both; Suzanne Medema; Eeke Thomee; Mark F Wildhagen; Nathalie Kapp
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

Review 4.  Clinical Utility of Mifepristone: Apprising the Expanding Horizons.

Authors:  Zalak V Karena; Harsh Shah; Hetvee Vaghela; Kalp Chauhan; Pranav K Desai; Asjad Raza Chitalwala
Journal:  Cureus       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.